TWC
VVOS icon

TD Waterhouse Canada’s Vivos Therapeutics VVOS Stock Holding History

TD Waterhouse Canada’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12
Closed -$51 – 2076
2024
Q4 		$51 Hold
12
– – ﹤0.01% 1912
2024
Q3 		$30 Hold
12
– – ﹤0.01% 1859
2024
Q2 		$28 Buy
+12
New +$29 ﹤0.01% 1877

Other funds holding VVOS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EL
EWA LLC Pittsbugh, Pennsylvania $548M AUM 35.14% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM

TD Waterhouse Canada's VVOS Position: Q1 2025 in Review

TD Waterhouse Canada sold out of Vivos Therapeutics (VVOS) in Q1 2025, closing a stake of 12 shares — an estimated $51 sold.

TD Waterhouse Canada first reported a position in VVOS in Q2 2024 and held it in 3 quarters. The position peaked at $51 in Q4 2024. 20 funds tracked by Wall St. Rank hold VVOS as of Q1 2025.

  • TD Waterhouse Canada reported no remaining Vivos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • TD Waterhouse Canada sold 12 Vivos Therapeutics shares in Q1 2025, an estimated $51.
  • TD Waterhouse Canada first reported a position in Vivos Therapeutics in Q2 2024 and held it in 3 quarters.
  • TD Waterhouse Canada's Vivos Therapeutics position peaked at $51 in Q4 2024.
  • 20 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2025.

Based on TD Waterhouse Canada's 13F filing for Q1 2025, filed 9 May 2025.